Overexpression of EGFR Protein in Bruneian Lung Cancer Patients

Han, Yu; Hamid, Mas R.W. Abdul; Telisinghe, Pemasari Upali; Hussin, Juniadah Binti Haji; Mabruk, Mohamed

doi:10.7314/apjcp.2015.16.1.233

Cited by 5 publications

(5 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Among our study patients, serum EGFR mRNA expression was similar in ADC and SCC. Most previous studies have shown higher EGFR expression in squamous cell morphology compared to adenocarcinoma, (Hirsch et al, 2003;Nakamura et al, 2006;Rusch et al, 1997;Ludovini et al, 2013) although others have shown opposite results (Sun et al, 2015;Han et al, 2015). The proportion of ADC patients in the present study group was much higher, hence this may have contributed to the similar baseline EGFR mRNA expression in both histological types.…”

Section: Discussionmentioning

confidence: 46%

“…The patients in the current study did not demonstrate any significant association between serum EGFR mRNA expression and various clinical characteristics such as age, gender, smoking status, disease stage or (Suwinski et al, 2012;Arfaoui et al, 2014) smoking status, (Zhuo et al, 2014Arfaoui et al, 2014) and advanced disease stage, (Sun et al, 2015;Arfaoui et al, 2014;Liang et al, 2012;Traynor et al, 2013) while several others have not. (Hirschet al, 2003;Brabender et al, 2001;Han et al, 2015;Liang et al, 2010). In the few studies that evaluated EGFR expression in blood, most included early stage disease undergoing surgical resection and did not find significant association between serum EGFR expression and clinical characteristics such as age, sex, or pathological subtype (Zhuo et al, 2014;Ciledag et al, 2008;Sasaki et al, 2003;Dziadziuszko et al, 2006).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Measurement of Serum EGFR mRNA Expression is a Reliable Predictor of Treatment Response and Survival Outcomes in Non- Small Cell Lung Cancer

Mohan

Ansari

Masroor

et al. 2020

Asian Pac J Cancer Prev

View full text Add to dashboard Cite

Background: EGFR over-expression plays a key role in the development and progression of lung cancer. However, its status as a prognostic biomarker for survival outcomes is unclear. Objectives: To evaluate the prognostic utility of serum EGFR mRNA expression in Non-Small cell lung cancer (NSCLC) for treatment response and survival. Methods: EGFR mRNA levels were determined in serum using quantitative reverse transcriptase polymerase chain reaction (qRT-PCR). Based on ROC curve, a cut off value of 16.0-fold increase was selected to categorize patients into low EGFR (≤ 16.0) and high EGFR (> 16.0) groups. Results: A total of 350 subjects were included (78.3% males), with mean (± SD) age of 57.1 (± 11.2) years, and including 247 (70.6%) adenocarcinoma (ADC). Majority (73.1%) had metastatic (stage IV) disease. Patients had higher pre-treatment serum EGFR mRNA levels than controls [median fold-increase (min, max), 16.2 (1.9, 66.7). Serum EGFR mRNA levels significantly reduced in those who achieved objective response and disease control. Significantly longer OS and PFS was observed in subjects having baseline EGFR mRNA expression ≤ 16.0 fold-increase compared to those with > 16.0 fold-increase [median (95% CI) OS: 25.0 (14.9, NR) versus 7.7 (6.3, 8.9) months; HR (95% CI) 2.9 (2.3, 4.0), p< 0.001; and PFS: 9.9 (7.1, 11.5) versus 6.0 (4.1, 7.5) months; HR (95% CI) 1.8 (1.3, 2.4), p< 0.001]. Conclusion: Serum EGFR mRNA expression is a useful parameter for predicting treatment response and survival outcomes in NSCLC.

show abstract

Section: Discussionmentioning

confidence: 46%

Section: Discussionmentioning

confidence: 99%

Measurement of Serum EGFR mRNA Expression is a Reliable Predictor of Treatment Response and Survival Outcomes in Non- Small Cell Lung Cancer

Mohan

Ansari

Masroor

et al. 2020

Asian Pac J Cancer Prev

View full text Add to dashboard Cite

show abstract

“…EGFR, a product of the proto-oncogene c-erbB1, is widely distributed on the surface of mammalian epithelial cells, fibroblasts, glial cells, keratinocytes, and other cell types. EGFR is a 170-kDa protein consisting of 3 domains: an extracellular domain that binds ligands, a transmembrane domain, and an intracellular domain with tyrosine kinase activity [ 24 ]. EGF binds with EGFR and induces tyrosine kinase phosphorylation of its intracellular domain [ 25 ], which then recruits effector proteins to its phosphorylated C-terminal domain and activates effector protein-mediated signal pathways that regulate proliferation, survival, differentiation, migration, invasion, and injury repair of cells [ 26 ].…”

Section: Discussionmentioning

confidence: 99%

Cyclic Guanosine Monophosphate (cGMP)-Dependent Protein Kinase II Blocks Epidermal Growth Factor (EGF)/Epidermal Growth Factor Receptor (EGFR)-Induced Biological Effects on Osteosarcoma Cells

Hua

Jiang

et al. 2018

Med Sci Monit

View full text Add to dashboard Cite

BackgroundThe present work was performed to detect the potential inhibitory effect of cyclic guanosine monophosphate (cGMP)-dependent protein kinase II (PKG II) on epidermal growth factor (EGF) receptor-induced biological activity and related signal cascades in osteosarcoma cells.Material/MethodsWe transfected the osteosarcoma MG-63 cell line with an adenoviral vector encoding PKG II cDNA (Ad-PKGII) and incubated the transfected cells with 250 μM 8-pCPT-cGMP to activate the PKG II. We stimulated the MG-63 cells with100 ng/ml EGF, and then detected their proliferation using a CCK-8 assay. Transwell assay was used to examine MG-63 cell migration; and Western blot analysis was used to detect expression of matrix metalloproteinase 9 (MMP-9) and activation of ERK and Akt.ResultsStimulating cells by 100 ng/ml EGF promoted MG-63 cell proliferation and migration, ERK and Akt phosphorylation, and MMP-9 expression. These effects of EGF were inhibited in MG-63 cells infected with Ad-PKGII and incubated with 8-pCPT-cGMP.ConclusionsOur results demonstrate that Ad-PKGII infection significantly inhibited EGF-induced proliferation and migration, as well as the associated-signal cascades; which indicates that PKG II might be a potential anti-cancer factor.

show abstract

“…[78] Epidermal growth factor receptor (erb-B1) is a member of the erbB family of tyrosine kinase receptor proteins. [79] Previous studies have shown that EGFR is expressed or highly expressed in various human tumor cells. [79] The overexpression of EGFR is attributed to gene amplification, which is noted to be about 12 copies per cell in relation to head and neck squamous cell carcinomas.…”

Section: Dna Methylation In Head and Neck Cancermentioning

confidence: 99%

“…[79] Previous studies have shown that EGFR is expressed or highly expressed in various human tumor cells. [79] The overexpression of EGFR is attributed to gene amplification, which is noted to be about 12 copies per cell in relation to head and neck squamous cell carcinomas. The constitutive EGFR activation caused via autocrine stimulation and through the coexpression of EGFR with its ligands, TGFα, has been observed and is indicative of its poor prognosis.…”

Section: Dna Methylation In Head and Neck Cancermentioning

confidence: 99%

Epigenetic Mechanisms in Head and Neck Cancer

Osorio¹,

Castillo²

2016

New Aspects in Molecular and Cellular Mechanisms of Human Carcinogenesis

View full text Add to dashboard Cite

Head and neck cancer HNC is one of the most prevalent human malignancies, affecting different anatomic sites of the upper aerodigestive tract U"DT such as the oral cavity, larynx, and naso-, oro-, and hypopharynx. HNC develops through the accumulation of multiple genetic and epigenetic alterations in a multistep process. In this issue, the aim is to describe epigenetic mechanisms behind HNC. The main mechanisms evaluated are DN" methylation, posttranslational histone modification, and noncoding RN"s.

show abstract

Overexpression of EGFR Protein in Bruneian Lung Cancer Patients

Cited by 5 publications

References 25 publications

Measurement of Serum EGFR mRNA Expression is a Reliable Predictor of Treatment Response and Survival Outcomes in Non- Small Cell Lung Cancer

Measurement of Serum EGFR mRNA Expression is a Reliable Predictor of Treatment Response and Survival Outcomes in Non- Small Cell Lung Cancer

Cyclic Guanosine Monophosphate (cGMP)-Dependent Protein Kinase II Blocks Epidermal Growth Factor (EGF)/Epidermal Growth Factor Receptor (EGFR)-Induced Biological Effects on Osteosarcoma Cells

Epigenetic Mechanisms in Head and Neck Cancer

Contact Info

Product

Resources

About